Tmunity Therapeutics Inc.

Months after receiving marketing authorisation for Yescarta (axicabtagene ciloleucel) in Singapore, Kite Pharma appears determined to pull out all the stops to widen access to its CAR T-cell therapy

Known for its blockbusters for infectious disease including Biktarvy (bictegravir/emtricitabine/tenofovir) for HIV and COVID-19 therapeutic Veklury (remdesivir), Gilead Sciences, Inc. is intending t

Gilead Sciences, Inc. 's Kite cell therapy unit is expanding through external investment, with the company announcing on 20 December that it will acquire privately held Tmunity Therapeutics Inc. for

The once-shocking $100m-plus venture capital round is not such a shock anymore in the biopharmaceutical sector, since the number of mega-rounds has increased over the last few years as drug developmen